Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QA108 granules for intermediate age-related macular degeneration (kidney yin deficiency and hyperactive yang pattern)
CTR20220759Phase 2Completed
- Sponsor
- Qiwei Biotech
- Start
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in age-related macular degeneration (AMD) comparing QA108 granules with Placebo (2 arms). Primary endpoint: Percent change in drusen area from baseline at week 24 in the study eye. Started Apr 2022; status: completed.
02
Drugs
QA108
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on CTR20220759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220759.